financetom
ANTX
financetom
/
Healthcare
/
ANTX
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
AN2 Therapeutics, Inc.ANTX
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
37.02M
Revenue (ttm)
n/a
Net Income (ttm)
-51.32M
Shares Out
30.10M
EPS (ttm)
-1.72
PE Ratio
n/a
Forward PE
n/a
Dividend
n/a
Ex-Dividend Date
n/a
Volume
15,936
Open
1.240
Previous Close
1.210
Day's Range
1.180 - 1.240
52-Week Range
0.870 - 3.070
Beta
-0.01
Analysts
Buy
Price Target
3.50 (+184.55%)
Earnings Date
May 13, 2025
Description >

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.

It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease.

The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Copyright 2023-2025 - www.financetom.com All Rights Reserved